Capmatinib hydrochloride is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with MET exon 14 mutations. It functions by selectively inhibiting the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. The substance is characterized by its ability to bind to the active site of the MET protein, thereby blocking its signaling pathways that promote cancer cell proliferation. Capmatinib hydrochloride is typically administered orally and is known for its favorable pharmacokinetic profile, including good bioavailability and a manageable side effect profile. The hydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. As with many targeted therapies, monitoring for specific biomarkers is essential for patient selection and treatment efficacy. Overall, Capmatinib hydrochloride represents a significant advancement in targeted cancer therapies, offering hope for patients with specific genetic alterations in their tumors.

Capmatinib dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Good efficacy in the treatment of non-small cell lung cancer (NSCLC) caused by MET 14 exon skipping mutations. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase
[1-3]
.

Capmatinib hydrochloride

1865733-40-9: Capmatinib hydrochloride is a small molecule inhibitor primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) with MET exon 14 mutations. It functions by selectively inhibiting the MET receptor tyrosine kinase, which plays a crucial role in tumor growth and metastasis. The substance is characterized by its ability to bind to the active site of the MET protein, thereby blocking its signaling pathways that promote cancer cell proliferation. Capmatinib hydrochloride is typically administered orally and is known for its favorable pharmacokinetic profile, including good bioavailability and a manageable side effect profile. The hydrochloride salt form enhances its solubility and stability, making it suitable for pharmaceutical formulations. As with many targeted therapies, monitoring for specific biomarkers is essential for patient selection and treatment efficacy. Overall, Capmatinib hydrochloride represents a significant advancement in targeted cancer therapies, offering hope for patients with specific genetic alterations in their tumors.

Capmatinib 2HCl.H2O

<p>Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.</p>

CAS 1865733-40-9

Capmatinib hydrochloride

Capmatinib 2HCl.H2O

Ref: 54-BUP10841

Capmatinib 2HCl.H2O

Ref: TM-T8825

Capmatinib Diydrochloride Monohydrate

Ref: ST-EA-CP-C134001